TargetMol

KNI-272

Product Code:
 
TAR-T27737
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27737-5mg5mg£1,171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27737-50mg50mg£2,303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27737-100mg100mg£3,042.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Kynostatin-272 is a HIV protease inhibitor. KNI-272 blocked the maturation of viral particles.
CAS:
147318-81-8
Formula:
C33H41N5O6S2
Molecular Weight:
667.84
Purity:
0.98
SMILES:
CSC[C@H](NC(=O)COc1cccc2cnccc12)C(=O)N[C@@H](Cc1ccccc1)[C@H](O)C(=O)N1CSC[C@H]1C(=O)NC(C)(C)C

References

1. Adachi M, Ohhara T, Kurihara K, Tamada T, Honjo E, Okazaki N, Arai S, Shoyama Y, Kimura K, Matsumura H, Sugiyama S, Adachi H, Takano K, Mori Y, Hidaka K, Kimura T, Hayashi Y, Kiso Y, Kuroki R. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4641-6. doi: 10.1073/pnas.0809400106. PubMed PMID: 19273847; PubMed Central PMCID: PMC2660780. 2. Matsumura H, Adachi M, Sugiyama S, Okada S, Yamakami M, Tamada T, Hidaka K, Hayashi Y, Kimura T, Kiso Y, Kitatani T, Maki S, Yoshikawa HY, Adachi H, Takano K, Murakami S, Inoue T, Kuroki R, Mori Y. Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Nov 1;64(Pt 11):1003-6. doi: 10.1107/S1744309108029679. PubMed PMID: 18997326; PubMed Central PMCID: PMC2581681. 3. Doi M, Kimura T, Ishida T, Kiso Y. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy-9-(isoquinolin-5-yloxy)-6-methylsulfanylmethyl-5,8-dioxo-4, 7-diazanonanoyl]-N-tert-butyl-1,3-thiazolidine-4-carboxamide. Acta Crystallogr B. 2004 Aug;60(Pt 4):433-7. PubMed PMID: 15258401. 4. Doi M, Ishida T, Katsuya Y, Sasaki M, Taniguchi T, Hasegawa H, Mimoto T, Kiso Y. KNI-272, a highly selective and potent peptidic HIV protease inhibitor. Acta Crystallogr C. 2001 Nov;57(Pt 11):1333-5. PubMed PMID: 11706266.